The anti-diabetic actions of a boarfish protein hydrolysate (BPH) were investigated in cultured cells and mice. A boarfish (Capros aper) muscle protein hydrolysate was generated using the enzymes Alcalase 2.4 L and Flavourzyme 500 L. Furthermore, the BPH was subjected to simulated gastrointestinal digestion (SGID). BPH and SGID samples (0.01-2.5 mg mL À1 ) were tested in vitro for DPP-IV inhibition and insulin and GLP-1 secretory activity from BRIN-BD11 and GLUTag cells, respectively. The BPH and SGID samples, caused a dose-dependent increase (4.2 to 5.3-fold, P < 0.001) in insulin secretion from BRIN-BD11 cells and inhibited DPP-IV activity (IC 50 1.18 AE 0.04 and 1.21 AE 0.04 mg mL À1 ), respectively. The SGID sample produced a 1.3-fold (P < 0.01) increase in GLP-1 secretion. An oral glucose tolerance test (OGTT) was conducted in healthy mice (n = 8), with or without BPH (50 mg/kg bodyweight). BPH mediated an increase in plasma insulin levels (AUC (0-120 min), P < 0.05) and a consequent reduction in blood glucose concentration (P < 0.01), after OGTT in mice versus controls. The BPH showed potent anti-diabetic actions in cells and improved glucose tolerance in mice.
Introduction
Population expansion combined with a reduction in arable farming land, has seen the exploration of natural therapeutics and bioactive food components shift from terrestrial organisms such as dairy, plant and animals to oceanic and coastal marine environments. Thus, bioactive mining of seaweeds, ichthyoids and crustaceous and bivalve organisms has increased (Senevirathne & Kim, 2012) . The oceans cover 70% of the earth's surface and is home to only 15% of all living organisms (Grosberg et al., 2012) ; however, it is widely accepted that marine proteins have the potential to yield a greater number of uncharacterised biologically active peptides than those from terrestrial protein sources (Wang et al., 2017) . Research into marine bioactive peptides has expanded exponentially over the past decade with improved protein extraction and hydrolysis methods and as such, has reaffirmed the importance of utilising all aspects of marine biomaterials (Senevirathne & Kim, 2012) .
Following on from the landmark Diabetes Control and Complications Trial (Nathan et al., 1993) , classical approaches to treating type-2 diabetes mellitus (T2DM) have been surpassed in favour of a more intensive hyperglycaemia management regime. Various strategies have been applied for the management of T2DM including dietary manipulation, lifestyle changes and medication (Bantle et al., 2008; Gibala et al., 2012; Inzucchi et al., 2012) . Development of anti-hyperglycaemic agents from dietary sources has gained impetus as these are generally less expensive to develop, have a reduced side-effects profile and are more accepted by the public (Fayaz et al., 2014; Gushiken et al., 2016) .
Proteins on their own generally only have a purely caloric effect on biological systems; however, hydrolysis of the protein can unlock peptides with clinical or health enhancing significance (Dhaval et al., 2016) . The discovery of marine bioactive components could contribute to novel strategies providing therapeutic benefit and better management of many common diseases. To date, many marine bioactive agents have been discovered displaying anti-obesity, anti-diabetic, antimicrobial, antihypertensive and anti-carcinogenic properties (Jensen & Maehre, 2016; Wang et al., 2017; Jin et al., 2018) . Fish protein is a rich but often unexploited source of bioactive peptides (Ryan et al., 2011; Kim et al., 2012; Urakova et al., 2012) . Capros aper commonly known as boarfish is an underutilised fish species that could provide a sustainable source of marine protein for bioactive peptide discovery for functional food development. Boarfish is a mesopelagic fish species distributed at depths of 40-600 m found abundantly in the Mediterranean and in the Northeast Atlantic stretching from Norway to Senegal (Whitehead et al., 1986) . Increased boarfish landings from Irish and Danish fishery fleets have paved the way for longterm storage and exploitation of this non-traditional species (White et al., 2011) .
Research into marine protein and its subsequent hydrolysates and isolated bioactive peptides targeting diabetes and its complications is limited. Nevertheless, some early studies have shown the beneficial effects of inhibiting dipeptidyl peptidase-4 (DPP-IV) (Huang et al., 2012; Harnedy et al., 2015 Harnedy et al., , 2018a Silaa et al., 2016) , and thus lowering glycated haemoglobin (HbA 1c ) in human volunteers with T2DM (Zhu et al., 2010) . The aims of the present study were firstly to investigate the in vitro insulinotropic and GLP-1 stimulatory effects of a BPH, and secondly to investigate the effect of oral consumption of BPH on blood glucose control in healthy mice following an oral glucose challenge.
Methods

Materials
H-Gly-Pro-7-amino-4-methyl coumarin (AMC), Diprotin-A (Ile-Pro-Ile), Leu-Trp-Met-Arg, Asp-Glu and Tyr.HCl were obtained from Bachem Feinchemikalien (Bubendorf, Switzerland). Alcalase Ò 2.4 L and Flavourzyme Ò 500 L were obtained from Novozymes A/S (Bagsvaerd, Denmark). Corolase PP was provided by AB Enzymes (Darmstadt, Germany) and BC pepsin was provided by Biocatalysts (Cardiff, UK). All other reagents including DPP-IV from porcine kidney (≥10 units per mg protein), were supplied by Sigma Chemical Company Ltd. (Wicklow, Ireland) . A GLP-1 ELISA assay kit was provided by Millipore (Hertfordshire, UK), lactate dehydrogenase (LDH) kit by Promega (Madison, WI, USA) and in vitro glucose uptake kit was provided by Cayman Chemicals (Ann Arbor, MI, USA).
Generation of a boarfish protein hydrolysate and its simulated gastrointestinal digested sample Samples of minced boarfish (Capros aper) meat were kindly provided by Killybegs Fishermen's Organisation, Killybegs, Co Donegal, Ireland, through Bord Iascaigh Mhara (BIM, Ireland) and stored at À20°C. Minced boarfish meat was suspended in distilled water to a final 6.83% (w/v) boarfish protein suspension and homogenised (94) at 24 000 r.p.m. min À1 for 15 s (Ultra-Turrax Ò T25 Basic, IKA Ò , Staufen, Germany). Hydrolysis was performed at 50°C and pH 7.0 with Alcalase 2.4 L and Flavourzyme 500 L at an enzyme:-substrate (E:S) ratio of 0.67% (v/w) for 4 h. Enzymes were inactivated by heating at 90°C for 20 min. Peptides were then separated by double filtration (Whatman grade 1: 11 lm), freeze-dried (FreeZone 18L, Labconco, MO, USA) and stored at À20°C until required.
In order to assess the likely retention of bioactivity following gastrointestinal (GI) digestion the boarfish protein hydrolysate (BPH) was subjected to simulated gastrointestinal digested (SGID) as described by Walsh et al. (2004) with modifications as described below. Briefly, the BPH (2.0% (w/v) protein equivalents) was incubated at 37°C and pH 2 for 90 min with pepsin at an E:S of 2.5% (w/w). The sample was adjusted to pH 7 and heat inactivated at 90°C for 20 min. The sample was incubated for 150 min at 37°C with Corolase PP (E:S of 1% (w/w)) and heat inactivated as before. The sample was subsequently freeze-dried and stored at À20°C (Harnedy et al., 2018a) .
Kjeldahl nitrogen quantification
The nitrogen content of the minced boarfish meat and BPH were quantified using the macro-Kjeldahl procedure as described previously (Connolly et al., 2013) . The nitrogen to protein conversion factor used was 6.25 (Kristinsson & Rasco, 2000) . All samples were analysed in triplicate (n = 3).
Physicochemical characterisation of protein hydrolysates
The peptide profiles of the BPH and SGID samples were determined by reverse-phase ultra-performance liquid chromatography (RP-UPLC (ACQUITY UPLC (Waters, Milford, MA, USA))) as described previously by Nongonierma & FitzGerald (2012) with modifications. In brief, the BPH and SGID samples were reconstituted at 0.5% (w/v) in mobile phase A (0.1% trifluoroacetic acid (TFA) in mass spectrometry (MS) grade H 2 O) and separated using an ACQUITY BEH 300 C18 RP column (2.1 9 50 mm, 1.7 lm; Waters, Milford, MA, USA) at 30°C. Mobile phase B was 0.1% TFA in 80% (v/v) MS grade acetonitrile (ACN) and the flow rate was set at 0.2 mL min The molecular mass distribution profiles of the samples were determined by gel permeation-high performance liquid chromatography (GP-HPLC) as described by Spellman et al. (2005) . In brief, the BPH and SGID samples were reconstituted at 0.8% (w/v) in a mobile phase of 0.1% TFA in 30% (v/v) HPLC grade ACN. The samples were separated by isocratic elution using a TSK G2000 SW separating column (600 9 7.5 mm ID) connected to a TSKGEL SW guard column (75 9 7.5 mm ID) at a flow rate of 1.0 mL min. The detector response was monitored at 214 nm. The molecular mass distribution of the proteins/peptides within the samples was determined from a calibration curve prepared from the average retention times of standard proteins and peptides. Insulin secretion studies in clonal pancreatic cells Acute insulin secretory effects of BPH and SGID samples were measured in vitro using clonal pancreatic BRIN-BD11 cells (McClenaghan et al., 1996) . Briefly, BRIN-BD11 cells were incubated for 20 min (acute test) with a range of hydrolysate concentrations (0.039-2.5 mg mL
À1
) in the presence of 5.6 mM glucose at 37°C. After 20 min the cell supernatant (900 lL) taken from the acute test wells were frozen at À20°C. Insulin was quantified using a dextran-coated charcoal radioimmunoassay (RIA), using crystalline rat insulin standard, guinea-pig anti-porcine antiserum (1:30 000 dilution) and 125 I-bovine standard (10 000 cpm), as described by Flatt & Bailey (1981) . The concentration of insulin in each sample was determined in duplicate (200 lL aliquots) from the prepared insulin standard curve ranging from 20 ng mL À1 stock to 0.039 ng mL À1 .
Cytotoxicity assay
To determine the cytotoxicity of the BPH and SGID samples on BRIN-BD11 cells, the release of LDH was measured in cell supernatants obtained from acute insulin-release experiments. LDH activity in the cell supernatants was determined using a CytoTox96 nonradioactive cytotoxicity assay kit (Promega, Madison, WI, USA), as per manufacturer's instructions. LDH results were compared to cells incubated with Krebs Ringer bicarbonate buffer (KRBB) supplemented with 5.6 mmol L À1 glucose alone.
In vitro GLP-1 secretions from GLUTag cell
In vitro effects of the BPH and the SGID samples on GLP-1 secretion were measured using the murine enteroendocrine GLUTag cell line kindly gifted to Ulster University by Professor Fiona Gribble at University of Cambridge, which originated from the laboratory of Dr Daniel Drucker, Toronto (Drucker et al., 1994) . Cells were cultured in high glucose (25 mM) Dulbecco's Modified Eagle's Medium as described previously (McLaughlin et al., 2016) . Cells were seeded into twenty-four well plates (150 000 cells per well) and allowed to attach overnight at 37°C. Following a pre-incubation step (1.1 mM glucose solution in KRBB for 40 min at 37°C), cells were incubated with the BPH and SGID samples (2.5 mg mL À1 ) prepared in 2 mM glucose (2 h at 37°C). Thereafter, 800 lL of experimental supernatant was collected and subsequently used to measure total GLP-1 release using an ELISA (Millipore, Hertfordshire, UK) as per manufacturer's protocol.
Dipeptidyl peptidase-4 (DPP-IV) inhibition in vitro
DPP-IV inhibition was determined with porcine kidney DPP-IV using an assay buffer consisting of 100 mM Tris-HCl, pH 8.0 as described previously (Harnedy et al., 2015) . All assays were performed in triplicate (n = 3). For DPP-IV inhibition, activity results were expressed as IC 50 values (inhibitory concentration, which inhibited DPP-IV activity by 50%).
Glucose uptake study using differentiated adipocytes Adipocyte (3T3-L1) cells were obtained from the American Type Culture Collection (ATCC, Manassas, Virginia, USA). Cellular glucose uptake studies were carried out as described by O'Harte et al., 2018. 3T3-L1 cells were seeded in a ninety-six blackwalled, clear bottom plate (2 9 10 4 cell per well; Greiner Bio-one, Germany) and left to attached overnight. Cells were treated with the test sample (100 lL) or control which were supplemented in glucose-free culture medium containing 150 lg mL À1 fluorescently tagged deoxyglucose analogue (2-NBDG) and incubated for 20 min. After incubation, the plate was then centrifuged for 5 min at 400 9 g at room temperature. The supernatant was aspirated and cells were washed with 200 lL cell-based assay buffer followed by further centrifugation for 5 min. The wash buffer was removed and 100 lL of cell-based assay buffer was added to all wells and the fluorescence was read immediately at 485 nm with emission measured at 535 nm using the FlexStation scanning fluorimeter (Molecular Devices, USA).
Intracellular calcium ([Ca
2+
]i) and membrane potential studies Monolayers of BRIN-BD11 cells were utilised to measure changes in [Ca 2+ ] i and membrane potential (Srinivasan et al., 2013) using fluorimetric Ca 2+ and membrane potential assay kits, respectively (Molecular Devices, Sunnyvale, CA, USA) as described by the manufacturer. Briefly, BRIN-BD11 cells were incubated with the BPH (2.5 mg mL À1 , at 37°C for 10 min) in the presence of 5.6 mM glucose. Alanine (10 mM) and KCl (10 mM) were used as positive controls. A Flexstation scanning fluorimeter with integrated fluid transfer was used for data acquisition (Molecular Devices, Rockville, MD, USA).
In vivo studies in healthy mice
Adult (3 months old) male National Institute of Health Swiss mice (NIH Swiss, Envigo, Bicester, UK) were housed individually in an air-conditioned room (22 AE 2°C) with a 12 h light: 12 h dark cycle (lights off between 20:00 and 08:00 h). Animals were maintained on a standard rodent chow (Teklad Global 18% Protein Rodent Diet; Harlan, UK; total energy 13.0 kJ g À1 ).
All animal experiments were carried out in accordance with the UK Animals (Scientific Procedures) Act 1986 and EU Directive 2010/63EU for animal experiments and approved by the Ulster University Animal Welfare and Ethical Review Committee. All necessary steps were observed to ameliorate any potential animal suffering. Overnight fasted (16 h) mice (n = 8) received glucose dissolved in physiological saline (pH 7.4) by oral gavage (18 mmol kg À1 body weight) or glucose (18 mmol kg À1 body weight) supplemented with the BPH dissolved in saline (50 mg kg À1 body weight). Blood samples were collected from the tail at various time points (from t = 0-120 min) as indicated in Fig. 6 and no adverse effects were observed. Blood glucose concentrations were measured using a Bayer Contour glucose monitor (Bayer, Newbury, UK). A small volume of blood (50-100 lL) was collected at each time point in fluoride oxalate coated tubes. Tubes were immediately centrifuged at 13 000 r.p.m. for 5 min and plasma stored in low protein binding Eppendorf tubes at À20°C until analysis. Circulating plasma insulin was measured in duplicate (10 lL aliquots) by RIA as described previously (Flatt & Bailey, 1981) .
Statistical analysis
All results were analysed using statistical software GraphPad Prism version 5.0 (GraphPad Software Inc., San Diego, CA, USA) and data presented as the mean AE SEM Statistical analyses were performed using the students unpaired t-test. Where appropriate, blood glucose data were compared using one-way and twoway analysis of variance (ANOVA), followed by StudentNewman-Keul's post hoc test. Data were considered to be significantly different when P < 0.05.
Results
RP-UPLC and molecular mass distribution profiles
The RP-UPLC profiles of the BPH and SGID samples indicate that further degradation of the hydrolysate occurred during SGID (Fig. 1) . Furthermore, the SGID sample has a greater percentage of smaller peptides <1 kDa (91.6%) compared to BPH (73.6%) as determined from molecular mass distribution profiles (Table 1) .
Inhibition of porcine DPP-IV activity
The effect of the BPH and its SGID sample on DPP-IV inhibition was examined. These showed DPP-IV inhibitory IC 50 values of 1.18 AE 0.04 mg mL À1 and 1.21 AE 0.04 mg mL À1 for the hydrolysate and SGID sample, respectively (Table 1) . Both samples exhibited Figure 1 Reverse phase ultra-performance liquid chromatography profile of boarfish (Capros aper) protein hydrolysate (BPH) and its simulated gastrointestinal digestion (BPH-SGID) sample. Separation of the BPH and BPH-SGID was carried out at 30°C, using a 2.1 9 100 mm, 1.7 lm Acquity UPLC C18 BEH column. The flow rate was set at 0.2 mL min potent DPP-IV inhibitory activity compared to the DPP-IV control without the addition of BPH. However, no significant difference in DPP-IV inhibition was observed between the BPH and SGID samples.
Insulin release from BRIN-BD11 cells
The BPH (from 0.078 to 2.5 mg mL À1 ) produced using a combination of the food-grade enzymes Alcalase 2.4 L and Flavourzyme 500 L, elicited a dose-dependent increase in insulin secretion from 1.5-4.2 fold (versus glucose alone) from clonal pancreatic BRIN-BD11 cells cultured at 5.6 mM glucose (Fig. 2a , P < 0.001). The insulinotropic activity of the BPH (2.5 mg mL À1 ) was further enhanced by the SGID process (5.3-fold increase; P < 0.001, Fig. 2b ) and was more marked when compared to a high concentration of GLP-1 (10 À6 M) which was the positive control (Fig. 2b) . The action of the BPH and SGID samples on insulin secretion was dependent upon their endogenous stimulatory actions and was not due to any cytotoxic cellular effects, as shown by the lack of LDH release, at all of the concentrations tested (Fig. 2c,d ).
GLP-1 secretion from GLUTag cells
Forskolin is a drug which is used to increase adenylyl cyclase activity and enhances intracellular cAMP and was used as a positive control for GLP-1 secretion. GLP-1 secretion from GLUTag cells was increased by 1.9-fold (P < 0.001) in the presence of the Forskolin Ò (10 mM) (Fig. 3 ) compared to the basal rate (25 mM glucose alone). The BPH at 2.5 mg mL À1 failed to stimulate GLP-1 secretion from GLUTag cells above the basal rate (1.1-fold, P > 0.05, Fig. 3 ). However, in contrast the BPH subjected to SGID elicited a 1.3-fold (P < 0.01, Fig. 3 ) increase over the basal rate. This response was significantly higher than that mediated by the BPH prior to SGID (P < 0.05, Fig. 3 ).
Glucose uptake in differentiated adipocytes
All experimental conditions contained KRBB without D-glucose (glucose free medium) with subsequent addition of 2-deoxyglucose (2-DG) with or without insulin (1 nM). The negative control, apegenin, showed that 2-DG uptake can be blocked in these differentiated 3T3-L1 cells whereas insulin (100 nM) can enhance 2-DG uptake (Fig. 4) . The BPH (2.5 mg mL À1 ) increased glucose uptake by 30% in 3T3-L1 adipocytes compared to the 2-DG only control KRBB in glucose free medium (P < 0.01, Fig. 4 ). This BPH effect was similar to the magnitude of glucose uptake observed with the lower dose of insulin (1 nM). The SGID sample also displayed a similar improved glucose uptake (30%) compared to the glucose free medium control (P < 0.01, Fig. 4) . Notably the combination of the BPH or SGID sample with low-dose insulin (1 nM) did not surpass the effect of either agent alone and thus there were not any statistically significant additive or synergistic effects present (P > 0.05; Fig. 4 ).
Intracellular calcium concentration and membrane potential studies
The BPH (2.5 mg mL
À1
) when tested on BRIN-BD11 cells resulted in a biphasic increase of [Ca 2+ ] i, including a small sharp increase, followed by gradual sustained increase throughout the 300 s test period, which was significantly greater than the 5.6 mM glucose control (P < 0.001, Fig. 5a ). In agreement, the integrated area under the curve (AUC (0-300 s) ) values were similar to the positive control (10 mM Alanine) and was significantly enhanced (12.5 to 12.8-fold) versus the glucose control (P < 0.001, Fig. 5c ). Similarly, the BPH produced an initial sharp increase in membrane potential, which by 100 s levelled out to just below basal levels (Fig. 5b) . The magnitude of membrane depolarisation was significantly lower compared to the positive control 10 mM KCl (P < 0.001, Fig. 5b ). Despite this the overall response from AUC (0-300 s) value was significantly higher for the BPH versus the 5.6 mM glucose control (P < 0.05, Fig. 5d ).
Glucose tolerance and insulin release in normal healthy mice
Oral administration of the BPH (50 mg kg À1 body weight) concomitantly with glucose in NIH Swiss mice Figure 4 Effect of a boarfish (Capros aper) hydrolysate generated with Alcalase 2.4 L and Flavourzyme 500 L and its simulated gastrointestinal digestion (SGID) sample on glucose uptake in cultured 3T3-L1 cells. Glucose uptake was measured in differentiated 3T3-L1 adipocytes using a fluorescent assay. Apigenin was used as a negative control and a high insulin 100 nM was used as a positive control. Boarfish hydrolysate and the SGID sample were analysed in the presence and absence of a low basal insulin (1 nM). Values are mean AE SEM (n = 3) **P < 0.01, ***P < 0.001 compared to the control (deoxyglucose in glucose free KRBB buffer). No significant differences were found between either BPH versus BPH + insulin or between SGID versus SGID + insulin.
resulted in a significant lowering of blood glucose concentrations at 15 min (P < 0.05), 30 min (P < 0.001) and 60 min (P < 0.05) compared to control mice receiving glucose alone (Fig. 6a) . This correlated to a significantly decreased integrated AUC (0-120 min) blood glucose concentration (22% reduction, P < 0.01, Fig. 6c ). The BPH-induced a corresponding increase in plasma insulin concentrations, which were moderately elevated, but failed to reach significance at individual time points (Fig. 6b) . Nevertheless, the overall integrated AUC (1-120 min) insulin response was significantly increased (36%, P < 0.05, Fig. 6d ) compared to the glucose control. Thus, overall oral administration of the BPH showed an enhanced acute insulinotropic response and a corresponding improved glucose tolerance in normal mice challenged with oral glucose.
Discussion
In the present study, our key findings demonstrated that orally administered BPH (50 mg mL À1 ) showed distinct anti-diabetic actions including in vivo insulin releasing responses and associated significantly improved glycaemic control following an oral glucose tolerance test (OGTT) in normal mice. This was in line with their pronounced insulinotropic actions in vitro. The present findings compare favourably with results published recently with other fish hydrolysates (Harnedy et al., 2018a,b) . For example, in the case of blue whiting (Micromesistius poutassou) a two-fold higher dose of protein hydrolysate (100 mg mL À1 ) generated using Alcalase 2.4 L and Flavourzyme 500 L had a similar acute glucose-lowering effect (22% AUC (0-120 min) reduction) following an OGTT in normal healthy mice (Harnedy et al., 2018a) . Furthermore, the in vitro anti-diabetic effects of protein hydrolysates derived from Atlantic salmon (Salmo salar) showed a similar profile to the BPH studied herein (Harnedy et al., 2018b) . Additionally, Cudennec et al. (2015) have demonstrated that a protein hydrolysate from cuttlefish (Sepia officinalis) exhibited DPP-IV inhibitory activity and GLP-1 releasing actions on secretin tumour cell line (STC-1) cells in vitro. Others have demonstrated that a collagen hydrolysate exhibited DPP-IV inhibitory activity and stimulated glucagonlike-peptide-1 (GLP-1) secretion in vitro (Iba et al., 2016) . Furthermore, they showed that a collagen hydrolysate also improved glucose tolerance in response to oral glucose in normal mice, which was thought to be mediated partially through enhanced GLP-1 secretion as well as inhibition of intestinal glucose uptake (Iba et al., 2016; Neves et al., 2017) .
The wide range of bioactivities contained within the marine environment has sparked much interest in terms of functional food ingredients and the potential for metabolic disease prevention and management (Zhu et al., 2010; Lordan et al., 2011; Drotningsvik et al., 2016) . To our knowledge, this is the first report of a protein hydrolysate derived from boarfish showing anti-diabetic potential. In the present study, acute incubation of cultured pancreatic BRIN-BD11 cells with a BPH, stimulated insulin secretion in a dosedependent manner. Interestingly, the insulin releasing action of the hydrolysate was not only retained, but improved following SGID, suggesting the possibility of improved oral efficacy and potency following gastrointestinal digestion. Acute treatment with the BPH or SGID samples did not affect pancreatic b-cell viability, as indicated by LDH assay results, reaffirming that the insulinotropic action was via a regulated physiological signalling pathway rather than simply caused by b-cell damage leading to unregulated insulin release.
Modulation of Ca
2+ handling by clonal beta cells is a key mechanism of the BPH-induced insulin release, although confirmation of this pathway by removing extracellular Ca 2+ or using a calcium channel blocker such as Verapamil Ò is required to verify the results obtained here (Ojo et al., 2014) . The membrane potential results revealed a depolarising phase in response to the BPH, which was complemented by a biphasic increase in intracellular Ca 2+ . The present finding suggests involvement of the b-cell K ATP channel in hydrolysate action.
GLP-1 and cholecystokinin-8 (CCK-8) secretion from cultured STC-1 cells has been used to screen for bioactivity of fish protein hydrolysate (Cudennec et al., 2012) and whey protein hydrolysate (Power-Grant et al., 2015) . Murine enteroendocrine GLUTag cells, have been previously utilised in the nutritional investigation of bioactive compounds and to screen for potential therapeutic agents affecting GLP-1 secretion as well as for investigating mechanisms of action (Brubaker et al., 1998; Brubaker & Anini, 2003) . The drug Forskolin Ò is a potent stimulator of cAMP production, which drives GLP-1 secretion (Reimann et al., 2008) and was used in the present study for comparison with the BPH related effects. Various nutrient dependant stimuli, including glucose and amino acids such as glutamine can trigger GLUTag membrane depolarisation by closure of ATP-sensitive potassium channel and Na + -coupled uptake and increased intracellular Ca 2+ through voltage-gated Ca 2+ channels (Reimann & Gribble, 2002; Gribble et al., 2003) . Other agents such as fatty acids and hormones could augment GLP-1 release by acting at points downstream of depolarisation. GLP-1 release from GLUTag cells have been linked to activation of PKA and PKC pathways (Gribble et al., 2003) . In vivo efficacy of peptides and hydrolysates hinge on their capacity to reach the target cells/membrane/receptor without losing this potency. The gastrointestinal (GI) tract is known to be a major barrier, encompassing digestive enzymes and sharp changes in pH which could influence structure and alter functional properties of peptides (M€ oller et al., 2008; Moughan et al., 2014) . Interestingly, in the present study GLP-1 release from GLUTag cells was enhanced after exposure to SGID, which could be a distinct advantage to incorporating a BPH as a dietary functional food ingredient. This may suggest higher oral bioavailability of the BPH after gastrointestinal digestion, or that perhaps the SGID step liberated further amino acids or small peptides that may exert a greater secretory action on GLUTag cells. The hydrolysate subjected to SGID also showed improved insulin secretion from BRIN-BD11 cells via membrane depolarisation and enhanced intracellular Ca 2+ fluxes and similar mechanisms could be facilitating its GLP-1 releasing effects, but further detailed mechanistic studies would be required to prove this link.
Recently peptide/protein interaction and inhibition of endogenous enzymes have emerged as a therapeutic approach to treating conditions such as hypertension (Furuta et al., 2016) and diabetes (Forbes et al., 2013; Harnedy et al., 2015) . The enzyme DPP-IV is present on cell membranes and in soluble form in blood plasma and is responsible for the rapid inactivation of GLP-1 and GIP (Mentlein et al., 1993) and therefore new oral DPP-IV inhibitors such as Vildagliptin Ò and Saxagliptin Ò have been developed to help with glycaemic management in T2DM (Ahr en et al., 2011; Chen et al., 2015) . The oral efficacy of BPH-derived peptides, which are absorbed in the small intestine, may play an important role in inhibiting DPP-IV activity. The clinical benefits of peptide and amino acid inhibition of DPP-IV and targeting this as a therapeutic strategy have been previously described (Nongonierma et al., 2013) . Here we showed that this DPP-IV inhibition was present at least in vitro with the BPH and SGID samples having similar IC 50 values (Table 1 ). In general, rodent studies have shown that a food protein hydrolysate having in vitro DPP-IV inhibitory activity, can also translate to antidiabetic effects in vivo (Nongonierma & FitzGerald, 2016) . It remains to be seen if the boarfish DPP-IV inhibitory action is due to a single peptide entity, or as seems more likely, a combination of several component peptides and thus further extensive characterisation work is required to help identify potent individual bioactive peptide(s) (Harnedy et al., 2015) .
3T3-L1 adipocyte cells were utilised to examine the ability of the BPH and SGID samples to stimulate glucose transport. 3T3-L1 adipocytes exhibit all the components of insulin receptor and signal transduction cascade and are frequently used to investigate insulin mediated glucose transport (Brubaker et al., 1998; Tang et al., 2016) . The BPH and SGID samples showed improved glucose uptake in 3T3-L1 cells (P < 0.01) which was similar to that of lower dose insulin (10 À9 M) alone, but it was not as potent as the higher insulin control (10 À7 M). The action of insulin in adipocytes is known to increase the number of functional glucose transporters, thus increasing the rate of glucose uptake (Simpson et al., 1983; Holman & Cushman, 1994; Shi & Kandror, 2008) . The BPH may act through improved activation or redistribution of glucose transporters, although further work is required to investigate their mode of action.
In conclusion, this study set out to display the potential therapeutic utility of a commonly underutilized protein source, namely the pelagic fish boarfish. A BPH displayed positive anti-diabetic like actions in a variety of in vitro assays (which was retained following SGID), and these bioactivities were supported from acute glucose tolerance studies in normal mice, demonstrating potent insulinotropic and glucose-lowering actions. Taken together our data suggest that a BPH represents a suitable target for development of functional food components for potential treatment of pre-diabetes or T2DM. Further assessment in chronic animal studies and in humans as well as peptide identification studies are required to confirm their potential.
